Month: February 2025

A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…

A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…

Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.

Antibody-drug conjugates (ADCs) have emerged as a promising treatment modality for pancreaticobiliary cancers, offering targeted delivery of cytotoxic agents while minimizing systemic toxicity. Dr. Lei Zheng’s presentation at the ASCO…

Presented by Dr. Susumu Hijioka at the ASCO Gastrointestinal Cancers Symposium, the STARTER-NET trial explores new frontiers in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are…

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) was held in San Francisco, USA. At this prestigious event, Cadonilimab, the world's first bispecific antibody developed in China, achieved multiple breakthroughs in the treatment of gastrointestinal cancers.Several research teams, including Professors Jing Huang and Wang Qu from the Cancer Hospital Chinese Academy of Medical Sciences, Professor Rongbo Lin from Fujian Cancer Hospital, and Professor Wan He from Shenzhen People's Hospital, presented the latest research findings on Cadonilimab in the treatment of advanced esophageal squamous cell carcinoma (ESCC), mismatch repair-proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer (mCRC), and locally advanced rectal cancer (LARC). These studies demonstrated the potential of Cadonilimab-based combination therapies to enhance anti-tumor efficacy, prolong survival, and improve safety, laying the foundation for a new era of bispecific antibody therapy in gastrointestinal cancers.

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients with HER2-positive gastric and esophageal cancer who had previously received anti-HER2 therapy but experienced disease progression. At the conference, a reporter from Oncology Frontier had the opportunity to conduct an exclusive interview with Dr. Kohei Shitara from the National Cancer Center Hospital in Japan regarding this study. The following is a summary of the discussion.

The landscape of systemic therapy for hepatocellular carcinoma (HCC) has undergone a major transformation, shifting from single-agent targeted or immunotherapies to dual immune checkpoint inhibitors and immune-targeted combination regimens. The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), held on January 23, 2025, highlighted two pivotal studies—CheckMate 9DW and CARES-310—focusing on dual immunotherapy strategies for previously untreated unresectable hepatocellular carcinoma (uHCC) and the impact of viral infection status on treatment outcomes.

In recent years, the emergence and breakthrough progress of multiple targeted and immunotherapy drugs, along with their combination regimens, have brought significant transformation to the systemic treatment of esophageal and gastric cancer. The field has evolved from monotherapy with targeted or immune agents to an era of dual or multi-immunotherapy combinations.